Xiamen Amoytop Biotech Co., Ltd. (SHA:688278)

Market Cap	28.54B
Revenue (ttm)	2.95B
Net Income (ttm)	880.92M
Shares Out	406.80M
EPS (ttm)	2.16
PE Ratio	32.51
Forward PE	24.05
Dividend	0.62 (0.87%)
Ex-Dividend Date	May 9, 2025

Volume	1,475,816
Average Volume	2,691,365
Open	72.00
Previous Close	72.17
Day's Range	72.00 - 73.55
52-Week Range	46.30 - 88.38
Beta	-0.32
RSI	47.35
Earnings Date	Aug 22, 2025

About Xiamen Amoytop Biotech

Xiamen Amoytop Biotech Co., Ltd. engages in research, development, production, and sale of recombinant protein drugs in China. The company provides solutions for diseases, such as viral hepatitis, malignant tumors, and immunotherapy. Xiamen Amoytop Biotech Co., Ltd. was founded in 1996 and is based in Xiamen, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 2,423
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688278

Financial Performance

In 2024, Xiamen Amoytop Biotech's revenue was 2.82 billion, an increase of 34.13% compared to the previous year's 2.10 billion. Earnings were 827.60 million, an increase of 49.00%.